The development and potential clinical utility of biomarkers for HDAC inhibitors

Drug discovery has always been a complex process including many phases from target validation to clinical development. Data from the Food and Drug Administration (FDA) has estimated that the elimination rate for investigational new drugs entering clinical trials is up to 80%. In recent years, many k...

Full description

Saved in:
Bibliographic Details
Published inDrug Discoveries & Therapeutics Vol. 7; no. 4; pp. 129 - 136
Main Authors Shi, Baowen, Xu, Wenfang
Format Journal Article
LanguageEnglish
Published Japan International Research and Cooperation Association for Bio & Socio-Sciences Advancement 01.08.2013
Subjects
Animals
Antineoplastic Agents - therapeutic use
biomarker
Biomarkers, Tumor - metabolism
cancer
Drug Discovery - methods
Gene Expression Regulation, Neoplastic - drug effects
Histone Deacetylase Inhibitors - therapeutic use
Histone Deacetylases - metabolism
Histone deactylase
Humans
inhibitors
Molecular Targeted Therapy
Neoplasms - drug therapy
Neoplasms - enzymology
Neoplasms - genetics
Neoplasms - pathology
Signal Transduction - drug effects
Treatment Outcome
Online AccessGet full text

Cover

More Information
Summary:Drug discovery has always been a complex process including many phases from target validation to clinical development. Data from the Food and Drug Administration (FDA) has estimated that the elimination rate for investigational new drugs entering clinical trials is up to 80%. In recent years, many kinds of biomarkers have been used to predict response in cancer treatment and for evaluation of new drugs. By increasing the understanding of histone deactylase (HDAC) inhibitors cellular mechanism of action, we have elucidated how HDAC inhibitors exert their effect by the use of proper biomarkers. In this paper, we mainly focus on the development and potential clinical utility of HDAC inhibitor biomarkers.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1881-7831
1881-784X
DOI:10.5582/ddt.2013.v7.4.129